First Invested:
Amount Invested:
Sector:
Web:

December 2007
£undisclosed
Pharmaceutical Research and Development
www.celentyx.com

Celentyx Ltd is a pharmaceutical research and development company based at the Birmingham Research Park. Celentyx was officially launched in March 2007 to commercially develop world-leading research from the University of Birmingham’s Medical School. The company uses a novel technology developed by the founders, called NCIP™ (Novel Clinical Identification Profiling™ ), to assess the suit ability of existing drugs in the treatment of new illnesses. This proprietary process uses clinically relevant human tissue and human cells to identify potential drugs.

Previous research from the Birmingham team has already shown the potential of medicines such as Prozac and drugs used to treat Parkinson’s disease as possible therapies for certain types of lymphoma and leukaemia. The company has two projects that are ready to enter Phase II clinical studies.